← Back to patent-cliff list
SNB-101
Tier C — Watch / tradeSNB-101
SN BioScience
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：TOP1
Indications (approved)：Small cell lung cancer, Gastric cancer, Colorectal cancer, Ovarian cancer, Breast cancer, Head and neck cancer, Pancreatic cancer
Regional status
US
-
EU
Phase II
2026-03-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of SNB-101?
Approved indications include: Small cell lung cancer, Gastric cancer, Colorectal cancer, Ovarian cancer, Breast cancer, Head and neck cancer, Pancreatic cancer.
When does the SNB-101 patent expire?
No public expiry year is available for SNB-101 yet; this page updates once verified.
How do I get a quote for SNB-101 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29